Acute respiratory distress syndrome (ARDS) is a common disorder globally, primarily affecting previously healthy individuals under the age of 65 [1] [2] [3] [4] . Up to 40% of affected patients die, with ARDS being responsible for a similar number of deaths as breast cancer, human immunodeficiency virus or myocardial infarction in the United States 1, 5, 6 . Many of those who do survive suffer from chronic respiratory, neurological and psychological morbidity 5, 7 .
Despite lower than expected mortality rates recorded in those patients with H1N1-related ARDS, and falling mortality rates in randomised controlled trials, it is not certain that there is an improved survival in the general population worldwide 8, 9 . Regardless of any recent improvement in supportive therapy, the mortality and morbidity associated with ARDS remain unacceptably high. Coupled with the consistent application of evidence-based supportive care, novel therapeutic interventions are urgently required to ensure a real reduction in the numbers dying from ARDS over the coming decades.
CURRENT TREATMENT STRATEGIES IN ARDS
Despite extensive research into the pathophysiology of ARDS and numerous clinical trials investigating potential therapies, the primary goal in the treatment of ARDS remains the optimisation of supportive care.
Supportive treatment
Ventilator management Protective mechanical ventilation (tidal volumes <6 ml/kg) is an expected standard of care in ARDS. Three major randomised clinical trials provide clear evidence that lung-protective, low tidal volume ventilation reduces mortality, with a relative risk reduction of up to 22% [10] [11] [12] . A small change in ventilator management may produce such significant improvements in mortality due to improved preservation of the alveolar epithelium barrier properties, down regulation of mechanosensitive pro-inflammatory pathways and reduced incidence of non-pulmonary organ dysfunction 13 .
However, further reductions in tidal volume (and plateau pressure) may be beneficial. Up to onethird of patients ventilated with low tidal volumes may still have alveolar hyperinflation, and patients with lower plateau pressures have lower mortality rates. Therefore a rational approach to ventilation may be to reduce tidal volume and plateau pressure as much as is feasible 10, [14] [15] [16] . Bein et al recently examined this strategy; by lowering tidal volumes to 3 ml/kg in conjunction with extracorporeal Co 2 removal, the number of ventilator days in those patients with the severest hypoxaemia was reduced 17 . larger trials are needed before such a strategy can be recommended in routine clinical practice, but in the meantime consistent application of tidal volumes not exceeding 5 to 6 ml/kg remains a cornerstone of ARDS treatment.
However, when ventilating any patient, physicians are faced with a myriad of options for controlling ventilator parameters. During the acute phase of ARDS, upwards of 30% of patients are paralysed with neuromuscular blocker drugs and managed with controlled modes of ventilation. More recently partial ventilatory support modes (where mechanical support is adjusted to patient need) are no longer reserved for use in weaning patients, but are now used in all phases of ventilation. limited evidence is available to equivocally support the exclusive use of either controlled or partial ventilator support modes, as no comparator studies were sufficiently powered to assess mortality. However, the observed beneficial effects of preserved spontaneous breathing with support modes, including improvements in gas exchange, haemodynamic parameters and nonpulmonary organ function, suggest that the use of partial ventilatory support modalities is often feasible in patients with ARDS and it may be associated with short-term physiological benefits 18 .
The application of positive end-expiratory pressure (PEEP) reopens collapsed alveoli, reduces intrapulmonary shunting, improves oxygenation and possibly reduces ventilator-induced lung injury 19, 20 . Several randomised controlled trials confirm improvements in oxygenation with higher PEEP, but failed to demonstrate an overall mortality benefit 21 . Nevertheless, higher PEEP in the most severely ill subgroup (i.e. Pao 2 /Fio 2 ratios <100 mmHg) resulted in improved survival, suggesting potential benefit in sicker patients 22 . Additionally, in those patients with life-threatening hypoxaemia, high PEEP may reduce the requirement for rescue therapies 23 . However, individual patient physiology is also important; higher levels of PEEP applied to patients with severe ARDS (Pao 2 /Fio 2 ratios <100 mmHg) results in additional recruitment of collapsed alveoli in only 50%, with the remainder developing over-distension. This finding suggests individual PEEP titration, rather than universal high PEEP strategies should be adopted 24 . Such an approach was recently examined in the Permissive Hypercapnia, Alveolar Recruitment and limited Airway Pressures (PHARlAP) trial; individualised PEEP titration and targeted plateau pressures resulted in improved oxygenation, pulmonary compliance and reduced expression of inflammatory cytokines. These findings are currently being investigated in a confirmatory Australian and New Zealand Intensive Care Society trial 25 .
Recruitment manoeuvres involve the sustained application of positive pressure to the ventilated lung in an attempt to reopen collapsed segments; they may improve oxygenation and have been considered as potential adjuncts to lung-protective ventilation 26, 27 . However, two large trials failed to demonstrate benefits with the routine use of recruitment manoeuvre protocols, but did confirm they are safe to apply 28, 29 . Recruitment manoeuvres may have a role to play in individual optimisation of ventilation strategies in severely hypoxaemic patients, but it remains to be elucidated how best to perform them and the optimal timing of their use 30 .
Fluid restriction
Fluid administration increases hydrostatic pressure in the lungs and promotes fluid filtration and oedema formation, particularly in states of increased microvascular permeability such as ARDS. A conservative fluid management strategy improves oxygenation and reduces duration of mechanical ventilation as a result of lower intravascular pressure and less extravascular lung water. Though no significant mortality difference was detectable, encouragingly there was no increase in the incidence of shock, or requirement for dialysis in patients assigned to a restrictive fluid regimen 31 . An even or negative fluid balance can be achieved clinically using renal replacement therapy, a diuretic or albumin combined with a diuretic 32, 33 . Though the ideal fluid-management strategy remains to be fully elucidated current evidence supports a conservative approach, aiming for at least a net even fluid balance in ARDS patients.
Rescue therapies

Prone position
Prone positioning improves oxygenation in patients with ARDS due to more uniform pleuralpressure gradients, a smaller volume of lung compressed by the heart and improved ventilationperfusion matching. The Prone-Supine 2 study group found that prone positioning, while improving gas exchange, had no effect on mortality; it also increased accidental extubations, airway obstruction and the incidence of hypotension 34 . At odds with these findings though, Charron et al in a retrospective analysis demonstrated a much lower than expected mortality in severely hypoxaemic patients, suggesting a potential clinical and physiological benefit in prone positioning 35 . Despite this conflicting evidence, prone positioning remains a rational approach for a patient whose hypoxaemia appears urgently life-threatening, but its effectiveness requires further confirmation before routine use can be recommended 35 .
High-frequency oscillatory ventilation
High-frequency oscillatory ventilation (HFoV) is a commonly used rescue therapy in severely hypoxaemic patients. HFoV holds the lungs inflated to maintain oxygenation; carbon dioxide is eliminated by delivering very small tidal volumes (approximately 1 to 2 ml/kg) at very high rates (3 to 15 breaths/second). This action is thought to minimise the repeated process of the opening and collapsing of lung units that causes alveolar injury during conventional mechanical ventilation. However, two recent, large multicentre trials conducted in Europe and North America failed to demonstrate any mortality benefit in patients receiving HFoV; moreover, one study suggested an increased mortality with HFoV use, accompanied by higher doses of sedation, neuromuscular blockade and use of vasoactive drugs. Taken together, these studies suggest that HFoV does not provide any benefits over and above a low tidal volume ventilator strategy and should not be used in routine care [36] [37] [38] .
Pulmonary vasodilators
Pulmonary vasodilators (nitric oxide [No], prostacyclin), directed at improving ventilationperfusion mismatch and pulmonary hypertension, are commonly used as rescue therapies in severely hypoxaemic patients. These agents transiently improve oxygenation, but are not associated with any mortality benefit; furthermore, an increased risk of renal impairment has been associated with the use of No [39] [40] [41] . on the other hand, recent work suggests that doses used in trials (typically 10 ppm) may actually represent 'over-dosing', thus leading to a deterioration in oxygenation over time and an increased risk of concomitant side-effects 42 . Current evidence does not support routine use of No in clinical practice; however, it may be a rational shortterm treatment in some patients with refractory hypoxaemia and should be used at the lowest possible dose to achieve clinical effect. Inhaled prostacyclin is significantly cheaper and easier to deliver than inhaled No; though lacking a major evidence base it may improve oxygenation and as such be justified as a therapy where NO is warranted but unavailable [43] [44] [45] .
Extracorporeal membrane oxygenation
Extracorporeal membrane oxygenation (ECMo) allows the dissociation of mechanical ventilation and gas exchange, enabling the lung to be ventilated with minimal risk of barotrauma while improving oxygen delivery and Co 2 removal. Use of ECMo in adults is confined to a few specialised centres, due in part to the expense and training required, but also due to disappointing results from previous randomised trials 46, 47 . Recent advances, including the standard use of the veno-venous route, improved pump technology and better management of anticoagulation, have resulted in renewed interest in ECMo. Survival rates of 79% in patients with H1N1associated ARDS treated with ECMo demonstrate the potential benefits of this technology in a wellselected group of patients 8 . The recent Conventional ventilatory support versus Extracorporeal membrane oxygenation for Severe Adult Respiratory failure (CESAR) trial randomised patients with severe ARDS to continued standard therapy in the patient's original hospital or consideration for ECMo (with transportation to a single ECMo centre). The trial demonstrated significantly greater survival at six months in those randomised to consideration for ECMo 48 . However, only 75% of patients randomised to the ECMo group received the therapy, making it difficult to separate the benefits of ECMO alone from the benefits associated with treatment in a specialised centre. Despite recent encouraging results, no trial has directly compared ECMo with standard care; it remains an expensive therapy associated with significant complications and is not widely available. Until these issues are addressed, ECMo will continue to be a rescue therapy reserved for use in the sickest cohort of patients with ARDS.
Extracorporeal Co 2 removal has the potential to optimise lung-protective ventilation by uncoupling oxygenation and carbon dioxide clearance in a select group of patients. Carbon dioxide removal is achieved via a sweep flow of oxygen across a heparinbonded membrane; these pumpless devices require minimal anticoagulation and are easily inserted at the bedside 49 . They are useful in the subset of patients where hypercapnia is a greater problem than oxygenation; in such circumstances, extracorporeal removal of Co 2 enables lower tidal volume ventilation. Major trials validating this device have not been performed, but animal studies suggest Co 2 removal devices can halve the minute ventilation required to achieve acid base homeostasis 50 . Extracorporeal Co 2 removal remains a rescue device suitable for a subgroup of patients where Co 2 elimination requires unacceptably high airway pressures or in centres where ECMo is unavailable.
PHARMAColoGICAl AGENTS IN ARDS
Multiple pharmacological therapies have been studied in ARDS with insufficient evidence found to support their use in clinical practice 51 . Major drug classes including beta agonists, anti-fungals, surfactant therapies, antioxidant therapies, immunomodulatory agents and antithrombotics all failed to show any mortality benefit in major trials (Table 1) .
However, a recent multicentre trial of early administration of cisatracurium for 48 hours to patients with severe ARDS found an improved, adjusted 90-day survival in the cisatracurium group.
Importantly, use of neuromuscular blocking drugs did not increase the rate of intensive care unit acquired weakness. It is postulated that the observed beneficial outcomes may be due to improved chest wall compliance, a reduction in oxygen consumption and a reduction in the expression of pulmonary and systemic pro-inflammatory cytokines 52 . Given this recent finding, it appears reasonable to use neuromuscular blocking agents in patients with refractory hypoxaemia for a short duration early in the course of their illness, until larger scale confirmatory trials are undertaken. Conflicting evidence continues to surround the role for corticosteroids in ARDS. In a major trial, the ARDS Network investigators failed to detect a mortality benefit in the steroid group, with a higher mortality observed in the subset of patients in whom randomisation occurred more than 13 days after the onset of ARDS 53 . Patients suffering from H1N1 infection similarly failed to derive any benefit from corticosteroid administration 54, 55 . However, Meduri et al found that patients who received methylprednisolone within 72 hours of ARDS diagnosis had improved oxygenation and reduced mortality 56 . Similarly, a meta-analysis of six clinical trials detected reduced mortality and improved oxygenation in patients administered early corticosteroids 57 . Administration of steroids in ARDS is likely to continue to incite debate, but given the conflicting evidence their use cannot be currently recommended for ARDS patients outside of clinical trials.
WHy HAVE WE FAIlED To DEVEloP EFFECTIVE THERAPIES?
Despite over 100 clinical trials of both supportive therapies and biological agents, the only unequivocally effective intervention over the last two decades has been the use of low tidal volume ventilation. There are many potential reasons why critical care, and ARDS research in particular, are labelled as the 'graveyard of clinical trials' (Table 2) .
First, patients with ARDS are a heterogeneous population, presenting with an array of comorbid disease and with a multitude of insults leading to the final pulmonary inflammatory phenotype; most patients die from causes other than ARDS, making it difficult to use mortality as an effective outcome marker 58 . Second, the American-European Consensus Conference definition of ARDS does not have adequate specificity-up to one-half of patients identified by this definition do not actually have the condition, leading to underpowered trials 59 . Third, underpowered trials may also be as a result of the decreasing control group mortality in the clinical trial population and due to geographical variations in ARDS incidence and mortality (a lower mortality has been reported in Australia than in Europe or North America) [60] [61] [62] . Finally, we have a limited understanding of underlying molecular mechanisms mediating lung injury. As a result, it has not been possible to develop lung-specific therapies that target the unique pulmonary pathogenic mechanisms in ARDS.
Progress is required in a number of areas to ensure future efforts investigating clinical and pharmacological interventions are conducted with Table 2 Potential reasons why ARDS trials have failed to detect any benefit, with potential changes that may be adapted to increase success of future trials 59 . The recent Berlin definition aimed to achieve this; however, when tested against the presence of diffuse alveolar damage at autopsy, it failed to improve significantly on the poor diagnostic capacity of its predecessor 63, 64 . Biomarkers combined with clinical variables could potentially be utilised as adjuncts in ARDS diagnosis, identifying subgroups of patients that would benefit from specific, targeted therapies. Some candidate biomarkers such as plasminogen activator inhibitor 1, thrombomodulin, interleukin 6 and interleukin 8 correlate with significant outcome variables in ARDS. However, trials remain small and it has not been possible to identify a single biomarker with adequate sensitivity and specificity. Identification of a panel of novel lung-specific biomarkers, whose expression is independent of systemic inflammatory processes, combined with clinical indices, holds the greatest promise for allowing the stratification of ARDS patients into therapeutic subgroups. However, as with other areas such as sepsis, identification of accurate biomarkers in such heterogeneous conditions remains challenging 65 . More accurate data regarding the true incidence and mortality in ARDS, and its geographical variation, will additionally assist in identifying appropriate subgroups and adequately powering trials. Finally, an improved understanding of molecular mechanisms underlying key pathological processes in ARDS (dysregulated pulmonary inflammation, alveolar barrier disruption, increased permeability of microvascular endothelium and dysregulated epithelial/endothelial repair) may assist in the identification of novel therapeutic strategies 13, [66] [67] [68] .
PoTENTIAl FUTURE THERAPIES IN ARDS
Investigation of numerous pharmacological agents has failed to demonstrate sufficient beneficial effect to warrant their use in clinical practice 51 . A novel approach is required and although many potential therapies remain conceptual there are a number of potential areas from which future therapies may be derived (Table 3) .
Pharmacological therapy
Hydroxymethylglutaryl-CoA reductase inhibitors ('statins') attenuate organ dysfunction in animal models of ARDS by reducing vascular leak and Adenosine regulates both endothelial barrier integrity and inflammatory cell trafficking in the lung and adenosine-dependent pathways improve pulmonary fluid homeostasis 70 as a result of enhanced fluid transport due to elevation of pulmonary cyclic adenosine monophosphate levels. Interferon beta has been shown to upregulate adenosine and dramatically attenuate vascular permeability in an ARDS model 71 . A Phase 2 clinical trial of the administration of recombinant human interferon beta 1a (FP-1201) showed a much lower than expected mortality in ARDS and a confirmatory Phase 3 trial will begin shortly 72 .
Other novel therapies
Mesenchymal stem cells are adult stem cells that have demonstrated therapeutic potential in experimental models of many inflammatory diseases, including ARDS. Beneficial effects observed are probably a result of immunomodulation by the newly introduced mesenchymal stem cells [73] [74] [75] [76] . However, this potential therapy currently remains conceptual and much work is required to elucidate mechanisms involved, identify suitable targets and develop appropriate delivery mechanisms.
Genetic variants that place some patients at risk where others remain protected following exposure to the same clinical insult are becoming increasingly understood, with polymorphisms of more than 25 genes associated with developing ARDS having been identified 13 . Gene-based therapies involving the delivery of genes or smaller nucleic acid sequences into the cell nucleus using a viral-based carrier may allow targeting and silencing or enhancement of such genetic polymorphisms. Additionally, other relevant genes in ARDS may be successfully manipulated for therapeutic gain. However, despite some promise in pre-clinical models, gene-based therapy is very much conceptual and multiple barriers exist, preventing its successful use in the lung [77] [78] [79] .
Recent evidence confirms that hypoxia is a potent pro-inflammatory stimulus in the lung, in addition to its well-known inflammatory effects in systemic organs. Therefore, regions of alveolar hypoxia may not be passive bystanders, but may actually contribute to the pathogenesis and progression of lung injury. However, the lung has unique molecular mechanisms governing its pro-inflammatory responses to hypoxia and the future elucidation of the molecular mechanisms behind pulmonary-specific hypoxia responses may provide a new route to developing lung-specific therapies in ARDS 80 .
CoNClUSIoN
ARDS remains a leading global public health concern. The introduction of low tidal volume ventilation strategies have reduced iatrgoneic lung injury and improved survival. However, other supportive therapies have failed to impact on mortality and many continue to have a limited evidence base. No pharmacological therapies aimed at this condition will be available in the foreseeable future. Future progress in the management of ARDS is likely to initially come from consistent application and refinement of current supportive therapies. However, we are slowly gaining an improved understanding of the pathophysiology of the condition, which may ultimately lead to the development of novel therapies. Testing of any new agents will be greatly facilitated by the evolution of a more accurate ARDS definition. Nonetheless, it is naïve to expect that any single therapy will be a 'magic bullet' treating all aspects of ARDS. Future progress is likely to be slow, incremental and multifaceted.
